ELEVANCE HEALTH, INC. (ELV) — financial distillation
Annual history (10-K)
Quarterly history (10-Q)
Two headline lines are shown to start. Click any item in a legend to add or remove it — every figure on the chart is one the table below also carries, for the period it names.
In brief, from the full filed history
- Revenue grew from $61.17B (period ending 2007-12-31) to $199.13B (period ending 2025-12-31) — a 6.8% annual pace across 18 year(s) of filed history.
- Net margin compressed from 5.5% to 2.8% over that same span.
- Across 55 tracked quarters, the strongest was $50.71B (quarter ending 2025-09-30) and the weakest was $14.43B (quarter ending 2010-06-30).
Annual — most recent 10-K
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $199.13B | 2025-12-31 | 10-K | 0001156039-26-000013 |
| Operating income | $7.20B | 2025-12-31 | 10-K | 0001156039-26-000013 |
| Net income | $5.66B | 2025-12-31 | 10-K | 0001156039-26-000013 |
| Diluted EPS | $25.21 | 2025-12-31 | 10-K | 0001156039-26-000013 |
| Total assets | $121.49B | 2025-12-31 | 10-K | 0001156039-26-000013 |
| Total liabilities | $77.47B | 2025-12-31 | 10-K | 0001156039-26-000013 |
| Cash & equivalents | $9.49B | 2025-12-31 | 10-K | 0001156039-26-000013 |
| Operating cash flow | $4.29B | 2025-12-31 | 10-K | 0001156039-26-000013 |
Quarterly — most recent 10-Q
| Line | Value | Period ends | Form | Filing |
|---|---|---|---|---|
| Revenue | $50.47B | 2026-06-30 | 10-Q | 0001156039-26-000060 |
| Operating income | $1.76B | 2026-06-30 | 10-Q | 0001156039-26-000060 |
| Net income | $1.46B | 2026-06-30 | 10-Q | 0001156039-26-000060 |
| Diluted EPS | $6.71 | 2026-06-30 | 10-Q | 0001156039-26-000060 |
| Total assets | $126.44B | 2026-06-30 | 10-Q | 0001156039-26-000060 |
| Total liabilities | $81.42B | 2026-06-30 | 10-Q | 0001156039-26-000060 |
| Cash & equivalents | $10.23B | 2026-06-30 | 10-Q | 0001156039-26-000060 |
| Operating cash flow | $4.33B | 2026-03-31 | 10-Q | 0001156039-26-000043 |
Reading
The figures above are taken directly from filings with the U.S. Securities and Exchange Commission. The reading below was generated by a local language model from only those figures; it introduces no numbers of its own. It is not investment advice.
Elevance Health, Inc. (ELV) operates on a substantial scale, with revenues surging to $199.13 billion in the fiscal year ending December 31, 2025. This growth trajectory, as evidenced by the multi-year trend, has unfolded at an annual pace of approximately 6.8% over 18 years. However, despite this robust revenue expansion, net margins have contracted from 5.5% to 2.8% during the same period.
The company’s financial performance is characterized by strong operating income and net income, standing at $7.20 billion and $5.66 billion respectively for the year ending December 31, 2025. Diluted EPS also reflects this profitability, reaching $25.21 in the same period. Elevance Health maintains a robust financial position with total assets of $121.49 billion and cash & equivalents of $9.49 billion as of December 31, 2025.
In examining quarterly figures, the company reported revenue of $50.47 billion and net income of $1.46 billion for the period ending June 30, 2026. The operating cash flow for the same period was $4.33 billion, indicating strong liquidity. Investors should monitor future filings to assess whether Elevance Health can sustain its revenue growth while addressing the ongoing compression in net margins.
Source: SEC EDGAR company facts for CIK 0001156039 · filings index